Qiu Q. Li
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 138 publications
Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom.
Journal: BMJ open
Published: December 08, 2025
GRP78 Selective Inhibitors From a Direct-to-Biology Strategy.
Journal: Angewandte Chemie (International ed. in English)
Published: October 30, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Journal: Frontiers in public health
Published: October 18, 2025
Cost-effectiveness of tarlatamab versus chemotherapy for patients with small-cell lung cancer after platinum-based chemotherapy in the United States and China.
Journal: Frontiers in pharmacology
Published: October 07, 2025
RUNX1/SLAMF3 Axis Drives Immunosuppression to Contribute to Colorectal Cancer Liver Metastasis by Blocking Phagocytosis and Depleting C1QC+ Tumor-Associated Macrophages.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 17, 2025
A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 07, 2025
Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study.
Journal: Frontiers in oncology
Published: January 02, 2025
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.
Journal: Lancet (London, England)
Published: December 10, 2024
Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors.
Journal: Signal transduction and targeted therapy
Published: November 17, 2024
Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.
Journal: Signal transduction and targeted therapy
Published: November 03, 2024
Last Updated: 09/26/2026